Histone Deacetylases as Targets for Multiple Diseases

被引：0
作者：
Sangshetti, Jaiprakash N. [1 ]
Sakle, Nikhil S. [1 ]
Dehghan, M. H. G. [1 ]
Shinde, Devanand B. [2 ]
机构：
[1] YB Chavan Coll Pharm, Aurangabad 431001, Maharashtra, India
[2] Dr BAM Univ, Dept Chem Technol, Aurangabad 431004, Maharashtra, India
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2013年 / 13卷 / 07期
关键词：
Histone deacetylase; Cancer; Non-cancer disorders; CANCER CELL-LINES; ACTIVITY IN-VITRO; ANTITUMOR-ACTIVITY; GENE-EXPRESSION; CYCLIC TETRAPEPTIDE; TRICHOSTATIN-A; LIFE-SPAN; ANTICANCER AGENTS; MYELOID-LEUKEMIA; TUMOR-CELLS;
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Inhibition of Histone deacetylases (HDACs) has been emerged as important approach to reverse aberrant epigenetic changes associated with various cancerous and non-cancerous diseases. The field of histone deacetylase inhibitors (HDIs) is moving into a new phase of development. The structure of histone deacetylases is well-established and the active sites have been well identified. Various drugs targeting this enzyme are in the pipeline for the treatment of different diseases. Since first-generation HDAC inhibitors proved their clinical fruitfulness and also second generation inhibitors are rationally designed with improved specificity, experts believe that this class will emerge in the treatment of various diseases. Considering these facts present review focuses on HDACs and developments of HDIs in the treatment of various diseases.
引用
收藏
页码：1005 / 1026
页数：22
相关论文
共 128 条
[1]   Decitabine increases fetal hemoglobin in Paplo anubis by increasing γ-globin gene transcription [J].
Akpan, Imo ;
Banzon, Virryan ;
Ibanez, Vinzon ;
Vaitkus, Kestis ;
DeSimone, Joseph ;
Lavelle, Donald .
EXPERIMENTAL HEMATOLOGY, 2010, 38 (11) :989-993
[2]   Targeting Histone Deacetylase Inhibitors for Anti-Malarial Therapy [J].
Andrews, Katherine T. ;
Tran, Thanh N. ;
Wheatley, Nicole C. ;
Fairlie, David P. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (03) :292-308
[3]   Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents [J].
Andrews, KT ;
Walduck, A ;
Kelso, MJ ;
Fairlie, DP ;
Saul, A ;
Parsons, PG .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2000, 30 (06) :761-768
[4]   Modulating molecular chaperone Hsp90 functions through reversible acetylation [J].
Aoyagi, S ;
Archer, TK .
TRENDS IN CELL BIOLOGY, 2005, 15 (11) :565-567
[5]   Effect of Directly Observed Therapy for Highly Active Antiretroviral Therapy on Virologic, Immunologic, and Adherence Outcomes: A Meta-Analysis and Systematic Review [J].
Arnsten, Julia H. ;
Litwin, Alain H. ;
Berg, Karina M. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 (01) :E33-E34
[6]   JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity [J].
Arts, Janine ;
King, Peter ;
Marien, Ann ;
Floren, Wim ;
Belien, Ann ;
Janssen, Lut ;
Pilatte, Isabelle ;
Roux, Bruno ;
Decrane, Laurence ;
Gilissen, Ron ;
Hickson, Ian ;
Vreys, Veronique ;
Cox, Eugene ;
Bol, Kees ;
Talloen, Willem ;
Goris, Ilse ;
Andries, Luc ;
Du Jardin, Marc ;
Janicot, Michel ;
Page, Martin ;
van Emelen, Kristof ;
Angibaud, Patrick .
CLINICAL CANCER RESEARCH, 2009, 15 (22) :6841-6851
[7]  
Atadja PW, 2011, PROG DRUG RES, V67, P175, DOI 10.1007/978-3-7643-8989-5_9
[8]   Signaling pathways in skeletal muscle remodeling [J].
Bassel-Duby, Rhonda ;
Olson, Eric N. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :19-37
[9]   The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines [J].
Batova, A ;
Shao, LE ;
Diccianni, MB ;
Yu, AL ;
Tanaka, T ;
Rephaeli, A ;
Nudelman, A ;
Yu, J .
BLOOD, 2002, 100 (09) :3319-3324
[10]   Malarial retinopathy: A newly established diagnostic sign in severe malaria [J].
Beare, Nicholas A. V. ;
Taylor, Terrie E. ;
Harding, Simon P. ;
Lewallen, Susan ;
Molyneux, Malcolm E. .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 75 (05) :790-797
12345678910